We expect to file our first IND in 2018.
| Program | Discovery | In vitro POC | In vivo POC | Clinical Candidate Selected | IND | Therapeutic Area |
| TIP™/SIP | ||||||
| TIP: Undisclosed Targets | Oncology | |||||
| SIP: Undisclosed Targets | Oncology | |||||
| Soluble vIgD™ | ||||||
| ALPN-101 (Fc-ICOS/CD28) | Inflammation | |||||
| Multi-Target Checkpoint Inhibitor | Oncology | |||||
| Localized vIgD™ | ||||||
| V-mAb ICOSL | Oncology | |||||
| Other targets | Oncology |
